Theses›Healthcare & bio›Photopharmacology in scope-reachable tissue

Photopharmacology in scope-reachable tissue

Light-switchable small molecules, not optogenetic gene therapy, win the first light-controlled therapies in tissue a scope or catheter can light (bladder, gut, airway, skin) by 2034, and the molecule owner captures it through pharma licensing

  • Bear
  • Early
  • $96M by 2035

The callLight-switched drugs would end systemic side effects in tissue a scope can reach, but the red-light chemistry has only worked in tadpoles and the market is tiny.

D1D2R1R2C1foragainst D1D2R1R2C1foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the restraints.
  1. D1A switch at 650 nm or longer reaches several millimetres into tissue through scopes doctors already use, removing the UV problem that stopped the first photoswitches.
  2. D2A small molecule avoids gene delivery and permanent expression, so it sidesteps the gene-therapy approval path optogenetics must take.
  3. R1One molecule has to switch red, stay inert in the dark, hold its on-state and survive reduction inside cells; so far that works in tadpoles and brain slices.
  4. R2The exits on record are Kiora at about $11M market value and Bayon for shares plus $7.1M of milestones; the 2035 market is under $100M.
  5. C1ABACUS-2, Kiora's 36-patient randomised Phase 2 of KIO-301 in retinitis pigmentosa, reads out: the first controlled human result for any photoswitch.Q3 2027
Rests onthe beliefs underneath
Supported by · confidence
What would prove itdated tests, open and resolved
202720282029203020312032today123456predictionswatch 202720282029203020312032today123456predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1Kiora completes ABACUS-2 enrolment or gives a dated topline window.Jun 2027 · open
  2. 2Kiora's ABACUS-2 reports a statistically significant improvement on its primary functional-vision endpoint by 31 Dec 2027.Dec 2027 · open
  3. 3By 31 Dec 2028 a peer-reviewed paper shows a photopharmacological agent switched at >=650 nm producing an in-vivo effect in a mammal at >=3 mm tissue depth.Dec 2028 · open
  4. 4A peer-reviewed red switch at 650 nm or longer works in a mammal at 3 mm or deeper.Dec 2028 · open
  5. 5By 31 Dec 2031 a photoswitchable drug activated at >=600 nm enters a registered human trial for a non-ocular indication.Dec 2031 · open
  6. 6A red-activated photoswitch enters a registered non-ocular human trial; a miss here ends the bet.Dec 2031 · open
Expressionslisted, private, technologies
Private · 6 private companies, 2 of them in Netherlands.

Bayon Therapeutics · Photoswitch Therapeutics · Lumobiotics · Lumox · LightOx · Genlumina

Technologies
Who has already bet on itprivate rounds, from public sources

$4M raised by 5 companies, $7M of it in the last three years. Early: Little money in so far; a lead investor would set the pace.

  • $2MLightOx Seed+, Jun 2024 $2M (GMC Life Sciences Fund (Praetura Ventures), Northstar Ventures) · Seed, 2021 $1M (Northstar Ventures, Northern Accelerator Seed Investment Fund)
  • $1MGenlumina
    • Founded 2024
     Seed, Jun 2025 (UNIIQ)
  • ·Lumobiotics
    • Founded 2017
     Grant
  • ·Bayon Therapeutics Rounds not itemised
  • ·Lumox Grant, Jul 2026 $5M (KWF Dutch Cancer Society)
What changedthe record, newest first
  • 12 Oct 2026Light-switchable drugs skip gene therapy, but they still need light to get in. The useful question is which tissue a scope or catheter can light, not which molecule is cleverest.